Why Did NRX Pharmaceuticals Stock Plunge 12.79%?

NRX Pharmaceuticals' stock price plummeted by 12.79% in pre-market trading on June 13, 2025, marking a significant downturn for the biopharmaceutical company.

NRX Pharmaceuticals reported a Q1 2025 net loss of $5.5 million, a slight improvement from the $6.5 million loss in the same period last year. The company's operating losses also decreased, indicating some progress in cost management.

NRX Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics based on its NMDA platform for treating central nervous system disorders. The company's innovative approach to drug development has garnered attention from analysts and investors alike.

Despite the recent stock price decline, some analysts remain optimistic about NRX Pharmaceuticals' long-term prospects. The average twelve-month price target for the stock is $28.50, with the highest target at $46. This suggests that investors believe in the company's potential for growth and success in the biopharmaceutical industry.